Hiromi Rakugi

Hiromi Rakugi

Auto-generated profile, based on publicly available information

Hiromi Rakugi

Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2014 in Hypertension Research
Verified
Journal Article
Closed access
PDF file
KSKazuaki Shimamoto
Kazuaki Shimamoto
KAKatsuyuki Ando
Katsuyuki Ando
TFToshiro Fujita
Toshiro Fujita
NHNaoyuki Hasebe
Naoyuki Hasebe
JHJitsuo Higaki
Jitsuo Higaki
JHJapanese Society of Hypertension Committee for Guidelines for the Management of Hypertension
Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension

1 September 2018 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
PDF file
MKMakoto Kinoshita
Makoto Kinoshita
KYKoutaro Yokote
Koutaro Yokote
HAHidenori Arai
Hidenori Arai
MIMami Iida
Mami Iida
YIYasushi Ishigaki
Yasushi Ishigaki
CAClinical Management of Atherosclerosis
Clinical Management of Atherosclerosis
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

2 July 2017 in Geriatrics & Gerontology International
Verified
Journal Article
Closed access
PDF file
YOYasuyoshi Ouchi
Yasuyoshi Ouchi
HRHiromi Rakugi
Hiromi Rakugi
HAHidenori Arai
Hidenori Arai
MAMasahiro Akishita
Masahiro Akishita
HIHideki Ito
Hideki Ito
OEon behalf of the Joint Committee of Japan Gerontological Society (JGLS) and Japan Geriatrics Society (JGS) on the definition and classification of the elderly
on behalf of the Joint Committee of Japan Gerontological Society (JGLS) and Japan Geriatrics Society (JGS) on the definition and classification of the elderly

1 June 2004 in Hypertension
Verified
Journal Article
Closed access
YIYoshio Iwashima
Yoshio Iwashima
TKTomohiro Katsuya
Tomohiro Katsuya
KIKazuhiko Ishikawa
Kazuhiko Ishikawa
NONoriyuki Ouchi
Noriyuki Ouchi
MOMitsuru Ohishi
Mitsuru Ohishi
TOToshio Ogihara
Toshio Ogihara
Adiponectin is one of the key molecules in the metabolic syndrome, and its concentration is decreased in obesity, type-2 diabetes, and coronary artery disease. Genetic investigation has revealed that 2 polymorphisms (I164T and G276T) are related to adiponectin concentration and diabetes. To examine whether adiponectin affects hypertension genetically or biologically, we performed a case-control study. A total of 446 diagnosed cases of hypertension (HT) in men and 312 normotensive (NT) men were enrolled in this study. Plasma adiponectin concentration was measured using an enzyme-linked immunosorbent assay system. Single nucleotide polymorphisms were determined by TaqMan polymerase chain reaction method. After adjustment for confounding factors, adiponectin concentration was significantly lower in HT (HT: 5.2±0.2 μg/mL; NT: 6.1±0.2 μg/mL; P <0.001). Furthermore, multiple regression analysis indicated that hypoadiponectinemia was an independent risk factor for hypertension ( P <0.001). Blood pressure was inversely associated with adiponectin concentration in normotensives regardless of insulin resistance. In subjects carrying the TC genotype of the I164T polymorphism, adiponectin concentration was significantly lower (TC: 2.6±0.9 μg/mL; TT: 5.5±0.1 μg/mL; P <0.01), and most of them had hypertension. In contrast, the G276T polymorphism was not associated with adiponectin concentration or hypertension. In conclusion, hypoadiponectinemia is a marker for predisposition to hypertension in men.

1 September 2003 in Hypertension
Verified
Journal Article
Closed access
NONoriyuki Ouchi
Noriyuki Ouchi
MOMitsuru Ohishi
Mitsuru Ohishi
SKShinji Kihara
Shinji Kihara
TFTohru Funahashi
Tohru Funahashi
TNTadashi Nakamura
Tadashi Nakamura
YMYuji Matsuzawa
Yuji Matsuzawa
Endothelial dysfunction is a crucial feature in the evolution of atherosclerosis. Adiponectin is an adipocyte-specific plasma protein with antiatherogenic and antidiabetic properties. In the present study, we investigated the relation between adiponectin and endothelium-dependent vasodilation. We analyzed endothelial function in 202 hypertensive patients, including those who were not taking any medication. Forearm blood flow was measured by strain-gauge plethysmography. Plasma adiponectin level was highly correlated with the vasodilator response to reactive hyperemia in the total ( r =0.257, P <0.001) and no-medication ( r =0.296, P =0.026) groups but not with nitroglycerin-induced hyperemia, indicating that adiponectin affected endothelium-dependent vasodilation. Multiple regression analysis of data from all hypertensive patients revealed that plasma adiponectin level was independently correlated with the vasodilator response to reactive hyperemia. Vascular reactivity was also analyzed in aortic rings from adiponectin-knockout (KO) and wild-type (WT) mice. Adiponectin-KO mice showed obesity, hyperglycemia, and hypertension compared with WT mice after 4 weeks on an atherogenic diet. Endothelium-dependent vasodilation in response to acetylcholine was significantly reduced in adiponectin-KO mice compared with WT mice, although no significant difference was observed in endothelium-independent vasodilation in response to sodium nitroprusside. Our observations suggest that hypoadiponectinemia is associated with impaired endothelium-dependent vasorelaxation and that the measurement of plasma adiponectin level might be helpful as a marker of endothelial dysfunction.

15 March 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
STShuko Takeda
Shuko Takeda
NSNaoyuki Sato
Naoyuki Sato
KUKozue Uchio-Yamada
Kozue Uchio-Yamada
KSKyoko Sawada
Kyoko Sawada
TKTakanori Kunieda
Takanori Kunieda
RMRyuichi Morishita
Ryuichi Morishita
Recent epidemiological studies suggest that diabetes mellitus is a strong risk factor for Alzheimer disease. However, the underlying mechanisms remain largely unknown. In this study, to investigate the pathophysiological interaction between these diseases, we generated animal models that reflect the pathologic conditions of both diseases. We crossed Alzheimer transgenic mice (APP23) with two types of diabetic mice ( ob / ob and NSY mice), and analyzed their metabolic and brain pathology. The onset of diabetes exacerbated Alzheimer-like cognitive dysfunction without an increase in brain amyloid-β burden in double-mutant (APP + - ob / ob ) mice. Notably, APP + - ob / ob mice showed cerebrovascular inflammation and severe amyloid angiopathy. Conversely, the cross-bred mice showed an accelerated diabetic phenotype compared with ob / ob mice, suggesting that Alzheimer amyloid pathology could aggravate diabetes. Similarly, APP + -NSY fusion mice showed more severe glucose intolerance compared with diabetic NSY mice. Furthermore, high-fat diet feeding induced severe memory deficits in APP + -NSY mice without an increase in brain amyloid-β load. Here, we created Alzheimer mouse models with early onset of cognitive dysfunction. Cerebrovascular changes and alteration in brain insulin signaling might play a pivotal role in this relationship. These findings could provide insights into this intensely debated association.